IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $46.00 Average Target Price from Brokerages

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have received a consensus recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and fourteen have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $46.00.

Several research firms have recently issued reports on IDYA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Wednesday, October 8th. Citigroup restated a “buy” rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th. The Goldman Sachs Group upped their price target on shares of IDEAYA Biosciences from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Tuesday, October 21st. Stephens reiterated an “overweight” rating and issued a $45.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th. Finally, New Street Research set a $30.00 price objective on IDEAYA Biosciences in a research report on Tuesday, October 21st.

Institutional Trading of IDEAYA Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd acquired a new stake in shares of IDEAYA Biosciences during the third quarter valued at $38,000. Abich Financial Wealth Management LLC purchased a new position in IDEAYA Biosciences in the 3rd quarter valued at about $58,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of IDEAYA Biosciences during the 2nd quarter worth about $61,000. CWM LLC grew its holdings in shares of IDEAYA Biosciences by 33.0% during the second quarter. CWM LLC now owns 3,153 shares of the company’s stock worth $66,000 after buying an additional 782 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its position in shares of IDEAYA Biosciences by 16.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after buying an additional 436 shares during the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Price Performance

IDYA opened at $33.85 on Friday. IDEAYA Biosciences has a 1-year low of $13.45 and a 1-year high of $37.08. The stock has a market cap of $2.97 billion, a P/E ratio of -18.20 and a beta of 0.05. The stock’s 50 day simple moving average is $33.57 and its 200 day simple moving average is $27.80.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $1.45. The firm had revenue of $207.83 million for the quarter, compared to analyst estimates of $59.98 million. Research analysts expect that IDEAYA Biosciences will post -3.07 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.